TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7667348

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 20% concentration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 30% concentration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 40% concentration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O) at 0% concentration (control)
Number of subjects: 10
Study: 2669565

Group type: EXPERIMENTAL
Intervention: Cow milk whey hydrolysate formula (NAN/HA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Conventional cow milk formula (Similac)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Soy-based formula (Isomil)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Exclusive breast feeding for greater than or equal to 4 months
Number of subjects: 72
Study: 5443385

Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine 60 mg
Number of subjects: 15
Study: 30472970

Group type: EXPERIMENTAL
Intervention: Mobile app with vegetable-based recipes and food tips
Number of subjects: 289
Study: 28631827

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 199

Group type: COMPARATOR
Intervention: Colonic resection
Number of subjects: 199
Study: 25926015

Group type: EXPERIMENTAL
Intervention: High-pitch helical scan first
Number of subjects: 303

Group type: COMPARATOR
Intervention: Conventional scan first
Number of subjects: 303
Study: 22607734

Group type: EXPERIMENTAL
Intervention: Long DRD4 allele carriers (seven or greater tandem repeats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long DRD4 allele
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short DRD4 homozygotes
Number of subjects: 0
Study: 21851643

Group type: EXPERIMENTAL
Intervention: 12-week physical activity group program with nutritional advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlisted group (control)
Number of subjects: 0
Study: 19148642

Group type: EXPERIMENTAL
Intervention: Mini incision (<10 cm)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard incision (15 cm)
Number of subjects: 62
Study: 17214932

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-Salvia miltiorrhiza treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 36
Study: 15019333

Group type: EXPERIMENTAL
Intervention: Arteriovenous sheathotomy surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (observation and laser treatment)
Number of subjects: 20
Study: 11352445

Group type: EXPERIMENTAL
Intervention: Probenecid 500mg twice daily for 2 days before moxifloxacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moxifloxacin 400mg
Number of subjects: 12
Study: 9165133

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. infusion on day 1) and 5-fluorouracil (1000 mg/m2 continuous i.v. infusion for 120 hours) followed by radiotherapy (64-70 Gy in 2 Gy per fraction, 5 times/week)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard treatment (radiotherapy or radiotherapy followed by surgery)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy
Number of subjects: 461
Study: 7970935

Group type: EXPERIMENTAL
Intervention: L-[2-15N]glutamine infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (4 infants)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: L-[1-13C]leucine infusion
Number of subjects: 11
Study: 3658434

Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.5%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 17
Study: 29196938

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal anesthesia (subarachnoid block - SAB)
Number of subjects: 0
Study: 28914366

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) with management interventions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 71
Study: 27734719

Group type: EXPERIMENTAL
Intervention: Artificial oocyte activation (AOA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no AOA)
Number of subjects: 21
Study: 24595568

Group type: EXPERIMENTAL
Intervention: Topical clofibrate
Number of subjects: 20
Study: 22618956

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 276

Group type: COMPARATOR
Intervention: Noncoated sutures
Number of subjects: 276
Study: 21194422

Group type: EXPERIMENTAL
Intervention: Artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Artesunate/amodiaquine (AS + AQ)
Number of subjects: 500
Study: 18245032

Group type: EXPERIMENTAL
Intervention: Olanzapine plus carbamazepine (10-30 mg/day plus 400-1200 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo plus carbamazepine (400-1200 mg/day)
Number of subjects: 118
Study: 16040445

Group type: EXPERIMENTAL
Intervention: SB (Single Bond)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NaOCl/SB (Sodium Hypochlorite + Single Bond)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SB/PL (Single Bond + Protect Liner)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NaOCl/SB/PL (Sodium Hypochlorite + Single Bond + Protect Liner)
Number of subjects: 24
Study: 11969360

Group type: EXPERIMENTAL
Intervention: Cefuroxime (100 mg/kg/day) IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dicloxacillin (200 mg/kg/day) plus Chloramphenicol (100 mg/kg/day) IV
Number of subjects: 40
Study: 10401446

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nortriptyline (adjusted to plasma concentration of 50-150 ng/ml)
Number of subjects: 81
Study: 8930007

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 732

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 732
Study: 2042462

Group type: EXPERIMENTAL
Intervention: Autologous blood donation prior to hip arthroplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no phlebotomy)
Number of subjects: 60
Study: 7240807

Group type: EXPERIMENTAL
Intervention: Subvirion influenza B vaccine (500 chick cell‐agglutinating units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole‐virus influenza B vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subvirion influenza B vaccine
Number of subjects: 0
Study: 30591465

Group type: EXPERIMENTAL
Intervention: FOLFIRI with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Number of subjects: 58
Study: 30407328

Group type: EXPERIMENTAL
Intervention: Electric blankets set to 38°C (group E)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Forced-air warmer set to 38°C (group F)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Forced-air warmer plus electric blankets set to 38°C (group FE)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (group E)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (group F)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (group FE)
Number of subjects: 443
Study: 26929803

Group type: EXPERIMENTAL
Intervention: Large drain (LD, 2.8‐mm‐diameter tube)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Small drain (SD, 1.6‐mm‐diameter tube)
Number of subjects: 77
Study: 24433926

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a i.m. weekly injected (group a)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 44 μg s.c. injected three times a week (group b)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Untreated (group c)
Number of subjects: 394
Study: 23103963

Group type: EXPERIMENTAL
Intervention: Freely evolving decision variable signal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic perturbation of the decision variable signal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domain general decision variable signal
Number of subjects: 0
Study: 19056572

Group type: EXPERIMENTAL
Intervention: FS50 (50 g/day, 264 kcal)
Number of subjects: 182

Group type: COMPARATOR
Intervention: LP (maize-soy flour, 71 g/day, 282 kcal)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: FS25 (25 g/day, 130 kcal)
Number of subjects: 182
Study: 17490492

Group type: EXPERIMENTAL
Intervention: Home visiting intervention with eight visits from a specially trained community nurse over two years and pro-active telephone support.
Number of subjects: 782
Study: 16802211

Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 132

Group type: COMPARATOR
Intervention: Endovenous laser therapy (EVLT) and Surgery
Number of subjects: 132
Study: 12957433

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20
Study: 10664643

Group type: EXPERIMENTAL
Intervention: Trained group (n = 50) received a training booklet in the mail 2 to 3 days prior to the scheduled appointment.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Informed group (n = 49) received a brief written summary of the major points contained in the training booklet while in the waiting room prior to the scheduled appointment.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Untrained group (n = 51) did not receive any form of communication skills intervention.
Number of subjects: 150
Study: 8862762

Group type: EXPERIMENTAL
Intervention: Acute bed-rest regime for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rigorous bed-rest regime for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal ambulatory conditions (control group)
Number of subjects: 30
Study: 1340807

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6347985

Group type: EXPERIMENTAL
Intervention: Zinc supplementation for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 31708999

Group type: EXPERIMENTAL
Intervention: Peer counselling intervention with a 10-day training course including practical sessions on breastfeeding techniques and challenges.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Peer counselling intervention
Number of subjects: 17
Study: 29803534

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (therapeutic dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg (supratherapeutic dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg after high-fat food intake
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (both doses)
Number of subjects: 48
Study: 27299459

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY-CS) at 2.5% concentration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY-CS) at 5% concentration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Reverse signaling activator EphB4/Fc
Number of subjects: 6

Group type: COMPARATOR
Intervention: PP2 (pyrophosphatase/phosphodiesterase2)
Number of subjects: 6
Study: 23712439

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1614
Study: 22342450

Group type: EXPERIMENTAL
Intervention: 6-month family-based behavioral intervention
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Reactive recruitment methods (mailings, TV ads, pamphlets)
Number of subjects: 270
Study: 19557206

Group type: EXPERIMENTAL
Intervention: Montelukast as add-on therapy
Number of subjects: 320
Study: 17577134

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg preoperatively
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 73
Study: 16354313

Group type: EXPERIMENTAL
Intervention: Sequential therapy (n=142; 4 cycles of cisplatin 75 mg/m2 I.V. on day 1 with etoposide 100 mg/m2 I.V. on days 1-3 followed by 4 cycles of topotecan 1.5 mg/m2 I.V. on days 1-5)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Alternating therapy (n=142; same doses of cisplatin/etoposide on cycles 1, 3, 5, and 7 and topotecan on cycles 2, 4, 6, and 8)
Number of subjects: 284
Study: 11880130

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) from Norplant users
Number of subjects: 40

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) from IUD users
Number of subjects: 40
Study: 10434322

Group type: COMPARATOR
Intervention: Group 1: No particular advice, possible referral for consultation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 2: Systematic referral for consultation 3 months post-surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 3: Planned consultation and test injection before surgery
Number of subjects: 45
Study: 7770366

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study: 2277574

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) 2.5 mg kg‐1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: d‐Tubocurarine (d‐TC) 50 micrograms kg‐1
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 54

Group type: COMPARATOR
Intervention: All groups (including Control)
Number of subjects: 54
Study: 7026817

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 65

Group type: COMPARATOR
Intervention: Various NSAIDs
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Preferred medication
Number of subjects: 65
Study: 31433343

Group type: EXPERIMENTAL
Intervention: Music with binaural beats (BB) for 30 minutes before sleep
Number of subjects: 43

Group type: COMPARATOR
Intervention: Music only (control group) for 30 minutes before sleep
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Music with binaural beats (BB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Music only (control group)
Number of subjects: 43
Study: 28476132

Group type: EXPERIMENTAL
Intervention: rebamipide 2% liquid
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: rebamipide 4% liquid
Number of subjects: 94

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study: 26491878

Group type: EXPERIMENTAL
Intervention: Behavioural support plus a PA intervention (supervised treadmill exercise plus PA consultations)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Behavioural support alone (control)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Behavioural support plus a PA intervention
Number of subjects: 785
Study: 23384634

Group type: EXPERIMENTAL
Intervention: Visual assessment of brain MRI in heart failure patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Visual assessment of brain MRI in control subjects
Number of subjects: 67
Study: 21489817

Group type: EXPERIMENTAL
Intervention: 12 months of valganciclovir prophylaxis
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 months of valganciclovir prophylaxis
Number of subjects: 38
Study: 19552876

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional acid-etched technique with Transbond (control)
Number of subjects: 34
Study: 17367439

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 15033254

Group type: EXPERIMENTAL
Intervention: Baseline N-terminal proatrial natriuretic peptide (Nt-proANP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 3-month changes in end-diastolic volume index
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 3-month E/A ratio
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Baseline Nt-proANP
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Maximal velocity of systolic pulmonary venous flow
Number of subjects: 71

Group type: COMPARATOR
Intervention: End-diastolic volume index
Number of subjects: 71

Group type: COMPARATOR
Intervention: End-systolic volume index
Number of subjects: 71
Study: 11346831

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) plus manual therapy of the cervical spine (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-energy shockwave therapy (group II)
Number of subjects: 30
Study: 9914664

Group type: EXPERIMENTAL
Intervention: Low self-esteem individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High self-esteem individuals
Number of subjects: 0
Study: 7822903

Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (1 g twice daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3126638

Group type: EXPERIMENTAL
Intervention: NTG oral spray (0.8 mg) in hydrosoluble solution (NTG-h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NTG oral spray (0.8 mg) in liposoluble solution (NTG-I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NTG oral spray (both formulations)
Number of subjects: 20
Study: 31055452

Group type: COMPARATOR
Intervention: double‐freeze CO2 cryotherapy (referent)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: single‐freeze CO2 cryotherapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: double‐freeze CryoPen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: single‐freeze CryoPen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: thermoablation
Number of subjects: 127
Study: 29118031

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 121

Group type: COMPARATOR
Intervention: Anthracycline therapy
Number of subjects: 121
Study: 26580081

Group type: EXPERIMENTAL
Intervention: Positive cognitive bias modification training for interpretation (CMB‐I)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Neutral training
Number of subjects: 87
Study: 22239608

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 35
Study: 21636566

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AMS-resistant subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AMS-susceptible subjects
Number of subjects: 20
Study: 18086027

Group type: EXPERIMENTAL
Intervention: Resin-based (RB) sealant
Number of subjects: 599

Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC) sealant
Number of subjects: 599
Study: 17062971

Group type: EXPERIMENTAL
Intervention: Cerebral oxyhemoglobin (O(2)Hb) during exercise in patients with IDC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygenation index (TOI) during exercise in patients with IDC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cerebral O(2)Hb in patients with reduced consciousness during exercise recovery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cerebral TOI in patients with reduced consciousness during exercise recovery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cerebral O(2)Hb in patients with ventricular tachycardia
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cerebral TOI in patients with ventricular tachycardia
Number of subjects: 42
Study: 14520129

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All treatments (Imipramine, Buspirone, Placebo)
Number of subjects: 40
Study: 14698074

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 6083
Study: 10651259

Group type: EXPERIMENTAL
Intervention: UCP2 insertion variant
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group (no UCP2 insertion variant)
Number of subjects: 744
Study: 7899651

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Group C0.5
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Group A0.5
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous morphine in Group C0
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Groups C0.5 and A0.5
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 45
Study: 2693031

Group type: EXPERIMENTAL
Intervention: Triflusal (platelet antiaggregant drug)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study: 1263176

Group type: EXPERIMENTAL
Intervention: Free collection service for transporting specimens and results
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of general practitioners
Number of subjects: 0
Study: 31421670

Group type: EXPERIMENTAL
Intervention: MOFA (0.2 g/kg fish oil preoperatively, followed by 48 h continuous infusion of 0.2 g/kg/d n3FA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard ERAS therapy)
Number of subjects: 100
Study: 27893184

Group type: EXPERIMENTAL
Intervention: Antidepressants and antipsychotics (specific drugs not detailed)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs with cardiovascular risk
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: CACNA1C rs1006737 SNP
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Risk drugs
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: CACNA1C rs1006737
Number of subjects: 728
Study: 26003273

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg single injection)
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Recombinant FSH (300 IU daily for first 7 days, then daily until three follicles reach ≥17 mm)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 1390